Ritu Baral


Top Analyst Cuts Price Target For Intercept Pharmaceuticals Inc (ICPT) By 50%; Here’s Why

Intercept Sank 40% in September following Dear Doctor and FDA warning letters; Ritu Baral weighs in.

Alnylam Pharmaceuticals, Inc. (ALNY) Picks Up a Price Target Boost from Cowen Following Stellar Phase III Top-Line Data in FAP

Analyst praises Alnylam’s patisiran as best-in-class, even more confident in its safety and tolerability profile.

Top Analyst Boosts Price Target for Aldeyra Therapeutics Inc (ALDX); Here’s Why

Ritu Baral sees 35% upside for Aldeyra on back of positive Phase 2a dry eye study.

Cowen Positive on Sarepta Therapeutics Inc (SRPT) Following Successful Early-Stage DMD Trial

Analyst upbeat on boosted dystrophin expression levels in Sarepta’s lead candidate golodirsen.

Cowen Sees High 80% Probability of FDA Approval for Insmed Incorporated’s (INSM) NTM Drug

Insmed’s lead asset ALIS poses compelling prospects for commercial success in the U.S.

Myokardia Inc (MYOK) Heart Drug Very Likely to Achieve FDA Breakthrough Status: Cowen

It is a nice time to be a Myokardia Inc (NASDAQ:MYOK) investor, particularly on back of the biotech firm’s successful Phase 2a PIONEER …

ACADIA Pharmaceuticals Inc. (ACAD) Nuplazid on a Roll, Marvels Cowen

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares are shooting up almost 17% with investors clearly paying keen attention to the biotech firm’s Parkinson’s Disease Psychosis …

Myokardia Inc (MYOK) Heart Drug Takes Next Beat Towards Finish Line; Cowen Boosts Price Target

Upon releasing positive data for lead drug candidate Mavacamten on Monday, investors flocked to Myokardia Inc (NASDAQ:MYOK), sending the stock soaring by 83%. …

GlycoMimetics Inc (GLYC) Shares Continue Fast Rally on Back of Promising Early Data in AML

What does GlycoMimetics Inc’s (NASDAQ:GLYC) abstract data for the American Society for Clinical Oncology (ASCO) bring to the table for acute myeloid leukemia …

Sarepta Therapeutics Inc (SRPT): Will Payors Reimburse Exondys 51?

Cowen analyst Ritu Baral is out with a new research note on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), as it appears that payors are still actively …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts